MedTrace Logo

Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs

NCT02089529 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-12-17

No results posted yet for this study

Summary

The following study investigates the role of information/expectancies in the response to Ibumetin and placebo.

The study is a double-blind randomized controlled trial with crossover, within subjects repeated measurements. The symptoms are measured by questionnaires. 40 patients will be included in the study. The administrated drug is Ibumetin 400 mg.

The study does not require patients to meet in the clinic. Patients will be instructed in how to report pain, tension and nervousness via mobile phone (Checkware AS, Trondheim, Norway).Three days a week for 12 weeks the patients are instructed to report at 0900 AM, and thereafter at 0910, 1100, 1300, 1500, 1700, and 1900 hrs each study day. At these times the patients will receive a sms where they are instructed to immediately rate their pain and stress level and report back.

Conditions

  • Axial Spondyloarthritis

Interventions

DRUG

Ibuprofen

Ibuprofen/Ibumetin with no information, positive information and neutral information

DRUG

Placebo

Placebo with no information, positive information and neutral information

Sponsors & Collaborators

  • University of Tromso

    collaborator OTHER

  • University Hospital of North Norway

    lead OTHER

Principal Investigators

  • Gunnstein Bakland, MD, phd · UNN

  • Magne Arve Flaten, psycol, phd · UIT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02089529 on ClinicalTrials.gov